Safety and tolerability of Neoral vs Sandimmune: 1-year data in primary renal allograft recipients. Neoral Study Group.
Barone
G
G
Department of Vascular and Transplant Surgery, University of Arkansas, USA.
Bunke
C M
CM
Choc
M G
MG
Hricik
D E
DE
Jin
J H
JH
Klein
J B
JB
Marsh
C L
CL
Min
D I
DI
Pescovitz
M D
MD
Pollak
R
R
Pruett
T L
TL
Stinson
J B
JB
Thompson
J S
JS
Vasquez
E
E
Waid
T
T
Wombolt
D G
DG
Wong
R L
RL
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D001794:Blood Pressure; D003404:Creatinine / Q000097:blood; D016572:Cyclosporine / Q000008:administration & dosage / Q000009:adverse effects*; D004311:Double-Blind Method; D005260:Female; D006084:Graft Rejection / Q000453:epidemiology; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects*; D016030:Kidney Transplantation / Q000276:immunology* / Q000502:physiology; D008297:Male; D008875:Middle Aged; D014184:Transplantation, Homologous
D007166:Immunosuppressive Agents; D016572:Cyclosporine; D003404:Creatinine